Literature DB >> 22582114

Therapeutic hypercapnia prevents bleomycin-induced pulmonary hypertension in neonatal rats by limiting macrophage-derived tumor necrosis factor-α.

A Charlotte P Sewing1, Crystal Kantores, Julijana Ivanovska, Alvin H Lee, Azhar Masood, Amish Jain, Patrick J McNamara, A Keith Tanswell, Robert P Jankov.   

Abstract

Bleomycin-induced lung injury is characterized in the neonatal rat by inflammation, arrested lung growth, and pulmonary hypertension (PHT), as observed in human infants with severe bronchopulmonary dysplasia. Inhalation of CO(2) (therapeutic hypercapnia) has been described to limit cytokine production and to have anti-inflammatory effects on the injured lung; we therefore hypothesized that therapeutic hypercapnia would prevent bleomycin-induced lung injury. Spontaneously breathing rat pups were treated with bleomycin (1 mg/kg/d ip) or saline vehicle from postnatal days 1-14 while being continuously exposed to 5% CO(2) (Pa(CO(2)) elevated by 15-20 mmHg), 7% CO(2) (Pa(CO(2)) elevated by 35 mmHg), or normocapnia. Bleomycin-treated animals exposed to 7%, but not 5%, CO(2), had significantly attenuated lung tissue macrophage influx and PHT, as evidenced by normalized pulmonary vascular resistance and right ventricular systolic function, decreased right ventricular hypertrophy, and attenuated remodeling of pulmonary resistance arteries. The level of CO(2) neither prevented increased tissue neutrophil influx nor led to improvements in decreased lung weight, septal thinning, impaired alveolarization, or decreased numbers of peripheral arteries. Bleomycin led to increased expression and content of lung tumor necrosis factor (TNF)-α, which was found to colocalize with tissue macrophages and to be attenuated by exposure to 7% CO(2). Inhibition of TNF-α signaling with the soluble TNF-2 receptor etanercept (0.4 mg/kg ip from days 1-14 on alternate days) prevented bleomycin-induced PHT without decreasing tissue macrophages and, similar to CO(2), had no effect on arrested alveolar development. Our findings are consistent with a preventive effect of therapeutic hypercapnia with 7% CO(2) on bleomycin-induced PHT via attenuation of macrophage-derived TNF-α. Neither tissue macrophages nor TNF-α appeared to contribute to arrested lung development induced by bleomycin. That 7% CO(2) normalized pulmonary vascular resistance and right ventricular function without improving inhibited airway and vascular development suggests that vascular hypoplasia does not contribute significantly to functional changes of PHT in this model.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22582114     DOI: 10.1152/ajplung.00072.2012

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  10 in total

1.  AAV delivery of tumor necrosis factor-α short hairpin RNA attenuates cold-induced pulmonary hypertension and pulmonary arterial remodeling.

Authors:  Patrick Crosswhite; Kai Chen; Zhongjie Sun
Journal:  Hypertension       Date:  2014-09-02       Impact factor: 10.190

2.  A glucocorticoid-receptor agonist ameliorates bleomycin-induced alveolar simplification in newborn rats.

Authors:  Shoichi Ishikawa; Tohru Ogihara; Shigeo Yamaoka; Jun Shinohara; Shigeru Kawabata; Yoshinobu Hirose; Daisuke Nishioka; Akira Ashida
Journal:  Pediatr Res       Date:  2022-09-06       Impact factor: 3.953

3.  HIV protease inhibitors in pulmonary hypertension: rationale and design of a pilot trial in idiopathic pulmonary arterial hypertension.

Authors:  Ying Li; Xiao-Hui Li; Zai-Xin Yu; Jing-Jing Cai; Timothy R Billiar; Alex F Chen; Ben Lv; Zi-Ying Chen; Zhi-Jun Huang; Guo-Ping Yang; Jie Song; Bin Liu; Hong Yuan
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

4.  Serotonin 2A receptor inhibition protects against the development of pulmonary hypertension and pulmonary vascular remodeling in neonatal mice.

Authors:  Cassidy Delaney; Laurie Sherlock; Susan Fisher; Joanne Maltzahn; Clyde Wright; Eva Nozik-Grayck
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-01-18       Impact factor: 5.464

5.  Pulmonary artery perfusion with anti-tumor necrosis factor alpha antibody reduces cardiopulmonary bypass-induced inflammatory lung injury in a rabbit model.

Authors:  Yang Yu; Mingxin Gao; Haitao Li; Fan Zhang; Chengxiong Gu
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

6.  Serum fibrinogen levels are positively correlated with advanced tumor stage and poor survival in patients with gastric cancer undergoing gastrectomy: a large cohort retrospective study.

Authors:  Xuefeng Yu; Fulan Hu; Qiang Yao; Chunfeng Li; Hongfeng Zhang; Yingwei Xue
Journal:  BMC Cancer       Date:  2016-07-14       Impact factor: 4.430

Review 7.  Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives.

Authors:  Scott D Collum; Javier Amione-Guerra; Ana S Cruz-Solbes; Amara DiFrancesco; Adriana M Hernandez; Ankit Hanmandlu; Keith Youker; Ashrith Guha; Harry Karmouty-Quintana
Journal:  Can Respir J       Date:  2017-02-13       Impact factor: 2.409

8.  Redistribution of Extracellular Superoxide Dismutase Causes Neonatal Pulmonary Vascular Remodeling and PH but Protects Against Experimental Bronchopulmonary Dysplasia.

Authors:  Laurie G Sherlock; Ashley Trumpie; Laura Hernandez-Lagunas; Sarah McKenna; Susan Fisher; Russell Bowler; Clyde J Wright; Cassidy Delaney; Eva Nozik-Grayck
Journal:  Antioxidants (Basel)       Date:  2018-03-14

Review 9.  Animal Models, Learning Lessons to Prevent and Treat Neonatal Chronic Lung Disease.

Authors:  Alan H Jobe
Journal:  Front Med (Lausanne)       Date:  2015-08-07

10.  Spironolactone attenuates bleomycin-induced pulmonary injury partially via modulating mononuclear phagocyte phenotype switching in circulating and alveolar compartments.

Authors:  Wen-Jie Ji; Yong-Qiang Ma; Xin Zhou; Yi-Dan Zhang; Rui-Yi Lu; Zhao-Zeng Guo; Hai-Ying Sun; Dao-Chuan Hu; Guo-Hong Yang; Yu-Ming Li; Lu-Qing Wei
Journal:  PLoS One       Date:  2013-11-19       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.